Xometry director Rosati proposes $651K share sale
The trust reported earlier sales of 8,100 shares on August 10, 2026, and 1,900 shares on August 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Xometry, Inc. (XMTR) reported a proposed sale for Fabio Rosati’s account, identifying him as a director, of 5,400 Class A Common Shares. The remarks state that all shares are to be sold by the Fabio Rosati 2022 Family Trust; the notice lists November 9, 2026, as the approximate sale date and $651,186 as the aggregate market value. Goldman Sachs & Co. LLC is named as broker. The proposed sale is made in connection with a selling plan dated August 10, 2026, intended to comply with Rule 10b5-1(c). The shares were acquired from the issuer through an option exercise on September 2, 2020.
Key Figures
Key Terms
Rule 10b5-1(c) regulatory
option exercise financial
selling plan financial
aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What plan is associated with Fabio Rosati’s proposed XMTR sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.